Barely Significant
← all excerpts

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy.

Eur J Haematol · 2026 · PMC12781150 · PMID 41116997

Europe PMCDOI
1
hedged sentence
0.0010
closest p · 0.0× alpha
0.0010
boldest claim

The sentences

highly significantp < 0.001actually significant
With a risk ratio of 2.82 and a highly significant p ‐value ( p < 0.001), the findings suggest that patients receiving ibrutinib are nearly three times more likely to develop hypertension compared to those in control groups.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.